Section Arrow
GERN.NASDAQ
- Geron Corp
Quotes are at least 15-min delayed:2026/03/21 11:43 EDT
Regular Hours
Last
 1.46
-0.09 (-5.81%)
Day High 
1.55 
Prev. Close
1.55 
1-M High
1.97 
Volume 
39.14M 
Bid
1.46
Ask
1.47
Day Low
1.45 
Open
1.55 
1-M Low
1.4 
Market Cap 
989.45M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.6 
20-SMA 1.63 
50-SMA 1.54 
52-W High 2.01 
52-W Low 1.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.13/0.04
Enterprise Value
1.11B
Balance Sheet
Book Value Per Share
0.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
183.88M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AZTRAzitra0.2828+0.1067+60.59%-- 
LNAILunai Bioworks Inc.0.4685+0.0835+21.69%-- 
DRMADermata Therapeutics Inc1.46+0.25+20.66%0.09PE
GERNGeron Corp1.46-0.09-5.81%-- 
IBRXImmunityBio8.47-0.35-3.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products foroncology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.